Shamburg News · 8-K filed Oct 9, 2026, 8:15 AM EDT

Atossa Therapeutics Executes Stapled CVR Agreement and Declares CVR Dividend

ATOS · ATOSSA THERAPEUTICS, INC.

  • Material agreement
  • Other event
  • Other
  • Materiality: high

On October 8, 2026, Atossa Therapeutics' Board declared a dividend of one stapled contingent value right per share of common stock outstanding at the close of business on October 19, 2026, and entered into a Stapled Contingent Value Rights Agreement with VStock Transfer, LLC as rights agent. The CVRs entitle holders, in the aggregate, to 25% of net proceeds from the sale or deemed monetization of the first qualifying FDA priority review voucher, subject to a $50 million cap and an outside date of December 31, 2036. No voucher has been awarded, and the company is under no obligation to develop or sell one.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 3.03, 8.01, 9.01, accession 0001193125-26-418560.

Written from the filing by Shamburg Markets. Figures are as reported by the company.